Exact Mass: 339.9741646
Exact Mass Matches: 339.9741646
Found 130 metabolites which its exact mass value is equals to given mass value 339.9741646,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
D-myo-Inositol 1,4-bisphosphate
D-myo-Inositol 1,4-bisphosphate belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. D-myo-Inositol 1,4-bisphosphate is an extremely weak basic (essentially neutral) compound (based on its pKa). D-myo-Inositol 1,4-bisphosphate is a substrate for several proteins including inositol polyphosphate 1-phosphatase, phosphatidylinositol 4,5-bisphosphate 5-phosphatase A, skeletal muscle and kidney enriched inositol phosphatase, and type I inositol-1,4,5-trisphosphate 5-phosphatase. 1D-Myo-inositol 1,4-bisphosphate is a substrate for Inositol polyphosphate 1-phosphatase, Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A, Skeletal muscle and kidney enriched inositol phosphatase and Type I inositol-1,4,5-trisphosphate 5-phosphatase. [HMDB]
alpha-D-Glucose 1,6-bisphosphate
Glucose 1,6-diphosphate (G-1,6-P2) is considered to be a major regulator of carbohydrate metabolism. It has been demonstrated that G-1,6-P2 is a potent activator (deinhibitor) of skeletal muscle phosphofructokinase (PFK) and phosphoglucomutase, while being an inhibitor of hexokinase (see Ref. 2). In addition, G-1,6-P2 has been shown to inhibit 6-phosphogluconate dehydrogenase in various rat tissues and fructose 1,6-bisphosphatase in bovine liver. Various factors and conditions affect the tissue content of G-1,6-P2. Specifically, anoxia induces a rapid fall in the content of G-l,6-P2 in the brain. Glucose 1,6-diphosphate has been recognized as a regulatory signal implicated in the control of metabolism, oxygen affinity of red cells, and other cellular functions. The levels of G 1,6-P2 are reduced in the liver and in the muscle of rats with experimentally induced diabetes. In muscle of genetically dystrophic mice, a decrease in the levels of G 1,6-P2 has been found, probably resulting from enhancement of glucose 1,6-P2 phosphatase activity. G 1,6-P2 is an inhibitor of hexokinase and its level is increased significantly after 5 min of exercise (~25\\%) and then decreased continuously. G 1,6-P2 is a potent allosteric activator of phosphofructokinase, and is markedly decreased in muscles of patients with glycogenosis type VII (muscle phosphofructokinase deficiency) and type V (muscle phosphorylase deficiency). Chronic alcohol intake produces an increase in the concentration of G 1,6-P2 in human muscle before the first sign of myopathy appears. When myopathy is present the level decreases to be similar to healthy humans. These changes could contribute to the decline in skeletal muscle performance (PMID:1449560, 2018547, 2003594, 3407759). Glucose 1,6-diphosphate is considered to be a major regulator of carbohydrate metabolism. It has been demonstrated that G-1,6-P2 is a potent activator (deinhibitor) of skeletal muscle phosphofructokinase (PFK) and phosphoglucomutase, while being an inhibitor of hexokinase (see Ref. 2). In addition, G-1,6 P2 has been shown to inhibit 6-phosphogluconate dehydrogenase in various rat tissues and fructose 1,6-bisphosphatase in bovine liver. Various factors and conditions affect the tissue content of G-1,6-P2. Specifically, anoxia induce a rapid fall in the content of G-l,6-P2 in brain. Glucose 1,6-diphosphate (G 1,6-P2 )have been recognized as a regulatory signal implicated in the control of metabolism, oxygen affinity of red cells and other cellular functions. The levels of G 1,6-P2 are reduced in the liver and in the muscle of rats with experimentally induced diabetes. In muscle of genetically dystrophic mice a decrease in the levels of G 1,6-P2 has been found, probably resulting from enhancement of glucose 1,6-P2 phosphatase activity. G 1,6-P2 is an inhibitor of hexokinase and its level is increased significantly after 5 min of exercise (~ 25\\%) and then decreased continuously. G 1,6-P2 is a potent allosteric activator of phosphofructokinase, and is markedly decreased in muscles of patients with glycogenosis type VII (muscle phosphofructokinase deficiency) and type V (muscle phosphorylase deficiency). Acquisition and generation of the data is financially supported in part by CREST/JST.
Fructose 1,6-bisphosphate
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C - Cardiovascular system > C01 - Cardiac therapy D007155 - Immunologic Factors D020011 - Protective Agents KEIO_ID F008
Bis(4-nitrophenyl) hydrogen phosphate
D004791 - Enzyme Inhibitors KEIO_ID B069
D-Fructose 2,6-bisphosphate
D-Fructose 2,6-bisphosphate (CAS: 77164-51-3), also known as phosphofructokinase activator, belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups. D-Fructose 2,6-bisphosphate is a regulatory molecule controlling the activity of the enzyme phosphofructokinase-1 or PFK1 (in mammals). PFK1, in turn, is the key regulatory enzyme in the central metabolic pathway glycolysis. D-Fructose 2,6-bisphosphate has the effect of increasing the activity of PFK1, thus increasing the rate at which the principle food molecule glucose is broken down. At the same time, this regulatory molecule also inhibits the opposing enzyme (FBPase1) in the reverse pathway (gluconeogenesis) so that the synthesis of glucose is not taking place in the same cell where glucose is being broken down (which would be wasteful). D-Fructose 2,6-bisphosphate is a regulatory molecule controlling the activity of the enzyme Phosphofructokinase-1 or PFK1 (in mammals). PFK1, in turn, is the key regulatory enzyme in the central metabolic pathway Glycolysis. D-Fructose 2,6-bisphosphate has the effect of increasing the activity of PFK1, thus increasing the rate at which the principle food molecule glucose is broken down. At the same time, this regulatory molecule also inhibits the opposing enzyme (FBPase1) in the reverse pathway (gluconeogenesis) so that the synthesis of glucose is not taking place in the same cell where glucose is being broken down (which would be wasteful) . [HMDB] KEIO_ID F010
D-myo-Inositol 1,3-bisphosphate
D-myo-Inositol 1,3-bisphosphate, also known as inositol 1,3-diphosphate, belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. D-myo-Inositol 1,3-bisphosphate is an extremely weak basic (essentially neutral) compound (based on its pKa). D-myo-Inositol 1,3-bisphosphate can be biosynthesized from inositol 1,3,4-trisphosphate through the action of the enzyme type II inositol 3,4-bisphosphate 4-phosphatase. The enzyme phosphatidylinositol 3-kinase (EC 2.7.1.137) catalyzes the production of this metabolite from 1-phosphatidyl-D-myo-inositol. D-myo-Inositol 1,3-bisphosphate is an intermediate in inositol phosphate metabolism. 1D-Myo-inositol 1,3-bisphosphate is an intermediate in inositol phosphate metabolism. The enzyme phosphatidylinositol 3-kinase [EC:2.7.1.137] catalyzes the production of this metabolite from 1-Phosphatidyl-D-myo-inositol. [HMDB]
D-myo-Inositol 3,4-bisphosphate
D-myo-Inositol 3,4-bisphosphate belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. D-myo-Inositol 3,4-bisphosphate is an extremely weak basic (essentially neutral) compound (based on its pKa). In humans, D-myo-inositol 3,4-bisphosphate participates in a number of enzymatic reactions. In particular, D-myo-inositol 3,4-bisphosphate can be biosynthesized from inositol 1,3,4-trisphosphate through the action of the enzyme inositol polyphosphate 1-phosphatase. D-myo-Inositol 3,4-bisphosphate is an intermediate in inositol phosphate metabolism. D-myo-Inositol 3,4-bisphosphate is converted from D-myo-inositol-3-phosphate via inositol polyphosphate-4-phosphatase (EC 3.1.3.66). 1D-myo-Inositol 3,4-bisphosphate is an intermediate in inositol phosphate metabolism. 1D-myo-Inositol 3,4-bisphosphate is converted from 1D-myo-inositol-3-phosphate via inositol polyphosphate-4-phosphatase [EC:3.1.3.66]. [HMDB]
Fructose 1,6-bisphosphate
Fructose 1,6-bisphosphate is fructose sugar or fructosephosphate that has been phosphorylated on carbons 1 and 6. The beta-D-form of this compound is very common in cells. The vast majority of glucose and fructose entering a cell is converted to fructose 1,6-bisphosphate at some point. Fructose 1,6-bisphosphate is a key component in the glycolysis metabolic pathway and is produced by phosphorylation of fructose 6-phosphate The enzyme phosphofructokinase uses ATP to transfer a phosphate group to fructose 6-phosphate to form fructose 1, 6-bisphosphate fructose. The enzyme aldolase splits fructose 1,6-bisphosphate into two sugars that are isomers of each other. These two sugars are dihydroxyacetone phosphate and glyceraldehyde phosphate. Fructose 1,6-bisphosphate is an allosteric activator of pyruvate kinase. The hydrolysis of fructose 1,6-bisphosphate is catalized by Fructose-1,6-bisphosphatase (fru-1,6-P2ase, EC 3.1.3.11) to fructose 6-phosphate and inorganic phosphate and provides a mechanism to permit the reversal of the glycolysis reaction (catalyzed by 6-phosphofructo-1-kinase).(OMIM) [HMDB]. D-Fructose 1,6-bisphosphate is found in many foods, some of which are garden cress, cascade huckleberry, wild celery, and devilfish. D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C - Cardiovascular system > C01 - Cardiac therapy D007155 - Immunologic Factors D020011 - Protective Agents
D-Tagatose 1,6-bisphosphate
D-Tagatose 1,6-bisphosphate is an intermediate in galactose metabolism. [HMDB] D-Tagatose 1,6-bisphosphate is an intermediate in galactose metabolism.
D-Mannose 1,6-bisphosphate
This compound belongs to the family of Hexose Phosphates. These are carbohydrate derivatives containing an hexose substituted by one or more phosphate groups.
1,6-Di-O-phosphono-D-fructose
Fructose-1,6-diphosphate
2,4,5-Trichloro-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide
C10H7Cl3N2O3S (339.9242962000001)
[(2R,3R)-2,3,5-Trihydroxy-4-oxo-6-phosphonooxyhexyl] dihydrogen phosphate
N-{[(4-Chloroanilino)carbonyl]oxy}-5-nitrothiophene-3-carboximidamide
5,7-dichloro-1,6-dihydroxy-3-methoxy-8-methyl-9H-xanthen-9-one|5,7-dichloro-3-O-methylnorlichexanthone
C15H10Cl2O5 (339.99052700000004)
2,5-Dichloro-1,3,6-trihydroxy-8-methylxanthone-3-Me ether
C15H10Cl2O5 (339.99052700000004)
4,5-Dichloronorlichexanthone-3-Me ether
C15H10Cl2O5 (339.99052700000004)
Harden-Young ester
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C - Cardiovascular system > C01 - Cardiac therapy D007155 - Immunologic Factors D020011 - Protective Agents The furanose form of D-fructose 1,6-bisphosphate. A D-fructofuranose 1,6-bisphosphate with a beta-configuration at the anomeric position.
dimethyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)chlorosilane
C8H10ClF9Si (340.00965579999996)
(3-Bromo-2-((4-chlorobenzyl)oxy)phenyl)boronic acid
1,2,4-TRIS(METHANESULFONYLOXY)BUTANE
C7H16O9S3 (339.99564460000005)
tert-butyl 3-bromo-5-nitro-1H-indole-1-carboxylate
C13H13BrN2O4 (340.00586380000004)
2-(bromomethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolane-4-methanol
C11H11BrCl2O3 (339.92685759999995)
2-(6-bromoquinolin-4-yl)-1-(6-methylpyridin-2-yl)ethanone
[4-[(3-bromophenyl)methoxy]-3-chlorophenyl]boronic acid
1-((2-BROMOPHENYL)SULFONYL)PIPERAZINE HYDROCHLORIDE
C10H14BrClN2O2S (339.96478340000004)
Ethyl 6,7-dichloro-3-(trifluoromethyl)-1,4-dihydroquinoxaline-2-carboxylate
C12H9Cl2F3N2O2 (339.99931499999997)
2-(7-bromoquinolin-4-yl)-1-(6-methylpyridin-2-yl)ethanone
Minodronic acid monohydrate
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
5-Fluoro-2-iodo-3-(5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridine
ethyl 4-(5-bromo-2-hydroxyphenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate
C13H13BrN2O4 (340.00586380000004)
6-[(5-bromotriazolo[4,5-b]pyrazin-3-yl)methyl]quinoline
(2-Bromophenyl)(diphenyl)phosphine
C18H14BrP (340.00164340000003)
3H-Indol-3-one,5-dromo-2-1,3-dihydro-3-oxo-2H-indol-2-ylidene-1,2-dihydro
Benzoic acid,5-bromo-2-[(3-chlorophenyl)methoxy]-
C14H10BrClO3 (339.95018000000005)
Benzoic acid,5-bromo-2-[(4-chlorophenyl)methoxy]-
C14H10BrClO3 (339.95018000000005)
L-Cystine, 1,1-dimethyl ester, hydrochloride
C8H18Cl2N2O4S2 (340.00850080000004)
Mercurate(1-), (4-carboxylatophenyl)hydroxy-
C7H5HgO3.H (340.00232459999995)
2,6-Dichloro-α-(4-chlorophenyl)-4-nitrobenzeneacetonitrile
(S)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL
C7H16O9S3 (339.99564460000005)
3-(4-BROMO-2-THIENYL)-1-(4-CHLORO-3-METHYLPHENYL)PROP-2-EN-1-ONE
C14H10BrClOS (339.93242200000003)
1,6-Di-O-phosphono-D-fructose
C26170 - Protective Agent > C2459 - Chemoprotective Agent > C2080 - Cytoprotective Agent D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D007155 - Immunologic Factors D020011 - Protective Agents
7-Chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone
C15H8ClF3N2O2 (340.02263739999995)
(5Z)-3-(1,1-dioxothiolan-3-yl)-5-(pyridin-3-ylmethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one
(2Z)-5-Bromo-2,3-biindole-2,3(1H,1H)-dione ammoniate
2,3-DI-O-Sulfo-alpha-D-glucopyranose
C6H12O12S2 (339.97701920000003)
p-Hydroxymercuribenzoate
C7H6HgO3- (340.00232459999995)
D010575 - Pesticides > D005659 - Fungicides, Industrial > D010663 - Phenylmercury Compounds D004791 - Enzyme Inhibitors > D006902 - Hydroxymercuribenzoates D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors D004791 - Enzyme Inhibitors > D008626 - Mercuribenzoates
Fructose-1,6-diphosphate
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C - Cardiovascular system > C01 - Cardiac therapy D007155 - Immunologic Factors D020011 - Protective Agents
[(2S,3R,4S,5R,6R)-2,3,5-trihydroxy-6-(phosphonooxymethyl)oxan-4-yl] dihydrogen phosphate
2-(2,4,5-Trichlorophenoxy)propionic acid trimethylsilyl ester
C12H15Cl3O3Si (339.98560100000003)
Fructose-2,6-diphosphate
A D-fructofuranose 2,6-bisphosphate with a beta-configuration at the anomeric centre.
D-Tagatofuranose 1,6-bisphosphate
The furanose form of D-tagatose 1,6-bisphosphate.
alpha-D-fructofuranose 1,6-bisphosphate
A D-fructofuranose 1,6-bisphosphate with an alpha-configuration at the anomeric position.
keto-D-fructose 1,6-bisphosphate
A ketohexose bisphosphate that is D-fructose substituted by phosphate groups at positions 1 and 6.
MNI137
MNI137 is a potent and selective negative allosteric modulator for group II mGluRs. MNI137 has IC50s values of 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization[1].
(1r,9r,10s,14s)-3-bromo-12,14-dihydroxy-13-methyl-2,8,11,13-tetraazatetracyclo[7.6.0.0²,⁶.0¹⁰,¹⁴]pentadeca-3,5,11-trien-7-one
2,4-dichloro-3,8-dihydroxy-6-methoxy-1-methylxanthen-9-one
C15H10Cl2O5 (339.99052700000004)
[(1s,2s,3r,4r,5s,6s)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxyphosphonic acid
[2,5-dihydroxy-6-(hydroxymethyl)-3-(sulfooxy)oxan-4-yl]oxidanesulfonic acid
C6H12O12S2 (339.97701920000003)
[(2r,3r,4r,5r)-3,4-dihydroxy-2-(hydroxymethyl)-5-[(phosphonooxy)methyl]oxolan-2-yl]oxyphosphonic acid
2,4-dichloro-1,3-dihydroxy-6-methoxy-8-methylxanthen-9-one
C15H10Cl2O5 (339.99052700000004)
2,4-dichloro-1,8-dihydroxy-5-methoxy-6-methylxanthen-9-one
C15H10Cl2O5 (339.99052700000004)